What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention?

Nicholas Curzen, Paul A. Gurbel, Aung Myat, Deepak L. Bhatt, Simon R. Redwood

Research output: Contribution to journalArticle

Abstract

Acute ST-segment elevation myocardial infarction (STEMI) is a dynamic, thrombus-driven event. As understanding of its pathophysiology has improved, the central role of platelets in initiation and orchestration of this process has become clear. Key components of STEMI include formation of occlusive thrombus, mediation and ultimately amplification of the local vascular inflammatory response resulting in increased vasoreactivity, oedema formation, and microvascular obstruction. Activation, degranulation, and aggregation of platelets are the platforms from which these components develop. Therefore, prompt, potent, and predictable antithrombotic therapy is needed to optimise clinical outcomes after primary percutaneous coronary intervention. We review present pharmacological and mechanical adjunctive therapies for reperfusion and ask what is the optimum combination when primary percutaneous coronary intervention is used as the mode of revascularisation in patients with STEMI.

Original languageEnglish (US)
Pages (from-to)633-641
Number of pages9
JournalThe Lancet
Volume382
Issue number9892
DOIs
StatePublished - 2013

Fingerprint

Percutaneous Coronary Intervention
Reperfusion
Thrombosis
Platelet Aggregation
Blood Vessels
Edema
Blood Platelets
Pharmacology
Therapeutics
ST Elevation Myocardial Infarction

ASJC Scopus subject areas

  • Medicine(all)

Cite this

What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention? / Curzen, Nicholas; Gurbel, Paul A.; Myat, Aung; Bhatt, Deepak L.; Redwood, Simon R.

In: The Lancet, Vol. 382, No. 9892, 2013, p. 633-641.

Research output: Contribution to journalArticle

Curzen, Nicholas ; Gurbel, Paul A. ; Myat, Aung ; Bhatt, Deepak L. ; Redwood, Simon R. / What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention?. In: The Lancet. 2013 ; Vol. 382, No. 9892. pp. 633-641.
@article{d4290d913eb6495db199489d3372bce9,
title = "What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention?",
abstract = "Acute ST-segment elevation myocardial infarction (STEMI) is a dynamic, thrombus-driven event. As understanding of its pathophysiology has improved, the central role of platelets in initiation and orchestration of this process has become clear. Key components of STEMI include formation of occlusive thrombus, mediation and ultimately amplification of the local vascular inflammatory response resulting in increased vasoreactivity, oedema formation, and microvascular obstruction. Activation, degranulation, and aggregation of platelets are the platforms from which these components develop. Therefore, prompt, potent, and predictable antithrombotic therapy is needed to optimise clinical outcomes after primary percutaneous coronary intervention. We review present pharmacological and mechanical adjunctive therapies for reperfusion and ask what is the optimum combination when primary percutaneous coronary intervention is used as the mode of revascularisation in patients with STEMI.",
author = "Nicholas Curzen and Gurbel, {Paul A.} and Aung Myat and Bhatt, {Deepak L.} and Redwood, {Simon R.}",
year = "2013",
doi = "10.1016/S0140-6736(13)61453-1",
language = "English (US)",
volume = "382",
pages = "633--641",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9892",

}

TY - JOUR

T1 - What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention?

AU - Curzen, Nicholas

AU - Gurbel, Paul A.

AU - Myat, Aung

AU - Bhatt, Deepak L.

AU - Redwood, Simon R.

PY - 2013

Y1 - 2013

N2 - Acute ST-segment elevation myocardial infarction (STEMI) is a dynamic, thrombus-driven event. As understanding of its pathophysiology has improved, the central role of platelets in initiation and orchestration of this process has become clear. Key components of STEMI include formation of occlusive thrombus, mediation and ultimately amplification of the local vascular inflammatory response resulting in increased vasoreactivity, oedema formation, and microvascular obstruction. Activation, degranulation, and aggregation of platelets are the platforms from which these components develop. Therefore, prompt, potent, and predictable antithrombotic therapy is needed to optimise clinical outcomes after primary percutaneous coronary intervention. We review present pharmacological and mechanical adjunctive therapies for reperfusion and ask what is the optimum combination when primary percutaneous coronary intervention is used as the mode of revascularisation in patients with STEMI.

AB - Acute ST-segment elevation myocardial infarction (STEMI) is a dynamic, thrombus-driven event. As understanding of its pathophysiology has improved, the central role of platelets in initiation and orchestration of this process has become clear. Key components of STEMI include formation of occlusive thrombus, mediation and ultimately amplification of the local vascular inflammatory response resulting in increased vasoreactivity, oedema formation, and microvascular obstruction. Activation, degranulation, and aggregation of platelets are the platforms from which these components develop. Therefore, prompt, potent, and predictable antithrombotic therapy is needed to optimise clinical outcomes after primary percutaneous coronary intervention. We review present pharmacological and mechanical adjunctive therapies for reperfusion and ask what is the optimum combination when primary percutaneous coronary intervention is used as the mode of revascularisation in patients with STEMI.

UR - http://www.scopus.com/inward/record.url?scp=84882252054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882252054&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(13)61453-1

DO - 10.1016/S0140-6736(13)61453-1

M3 - Article

C2 - 23953387

AN - SCOPUS:84882252054

VL - 382

SP - 633

EP - 641

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9892

ER -